Trodelvy(sacituzumab govitecan)
Trodelvy (sacituzumab govitecan) is an antibody drug conjugate pharmaceutical. Sacituzumab govitecan was first approved as Trodelvy on 2020-04-22. It is used to treat triple negative breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms and triple negative breast neoplasms. The pharmaceutical is active against tumor-associated calcium signal transducer 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Trodelvy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Sacituzumab govitecan
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Trodelvy | sacituzumab govitecan-hziy | Gilead Sciences | N-761115 RX | 2020-04-22 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| trodelvy | Biologic Licensing Application | 2025-03-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| triple negative breast neoplasms | — | D064726 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9317 | Injection, sacituzumab govitecan-hziy, 2.5 mg |
Clinical
Clinical Trials
142 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 7 | 18 | 7 | — | 1 | 28 |
| Triple negative breast neoplasms | D064726 | — | — | 5 | 14 | 7 | — | 1 | 22 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 4 | 2 | — | — | 6 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 3 | 8 | — | — | — | 9 |
| Urinary bladder neoplasms | D001749 | — | C67 | 4 | 5 | — | — | — | 6 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | 3 | — | — | — | 4 |
| Urologic neoplasms | D014571 | — | C64-C68 | 3 | 4 | — | — | — | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 2 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 1 | — | — | — | 3 |
| Transitional cell carcinoma | D002295 | — | — | 2 | 3 | — | — | — | 3 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | 2 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sacituzumab govitecan |
| INN | sacituzumab govitecan |
| Description | Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies; antineoplastics (camptothecin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545262 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12893 |
| UNII ID | M9BYU8XDQ6 (ChemIDplus, GSRS) |
Target
Agency Approved
TACSTD2
TACSTD2
Organism
Homo sapiens
Gene name
TACSTD2
Gene synonyms
GA733-1, M1S1, TROP2
NCBI Gene ID
Protein name
tumor-associated calcium signal transducer 2
Protein synonyms
40kD glycoprotein, identified by monoclonal antibody GA733, Cell surface glycoprotein Trop-2, cell surface glycoprotein TROP2, epithelial glycoprotein-1, gastrointestinal tumor-associated antigen GA7331, Membrane component chromosome 1 surface marker 1, membrane component, chromosome 1, surface marker 1, Pancreatic carcinoma marker protein GA733-1, pancreatic carcinoma marker protein GA7331, trophoblast cell surface antigen 2
Uniprot ID
Mouse ortholog
Tacstd2 (56753)
tumor-associated calcium signal transducer 2 (Q8BGV3)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Trodelvy – Gilead Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,740 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trodelvy
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,759 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use